Home
CRIS

CRIS

Curis Inc.

as of 12-05-2025 1:32pm EST

$1.36

+$0.01

+0.74%

Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Chart Type:

Time Range:

Founded:	2000	Country:	United States
Employees:	N/A	City:	LEXINGTON
Market Cap:	14.6M	IPO Year:	2000
Target Price:	$16.50	AVG Volume (30 days):	113.7K
Analyst Decision:	Strong Buy	Number of Analysts:	2
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-3.28	EPS Growth:	N/A
52 Week Low/High:	$1.02 - $4.50	Next Earning Date:	11-06-2025
Revenue:	$11,650,000	Revenue Growth:	13.56%
Revenue Growth (this year):	6.13%	Revenue Growth (next year):	8.44%

AI-Powered CRIS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold

Model Accuracy: 72.48%

72.48%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full CRIS Forecast & Prediction with Hourly Data

Compare CRIS vs Leading Stocks

See how CRIS stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free CRIS Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "CRIS Curis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.